These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35935587)

  • 1. Identification of Genes Predicting Poor Response of Trastuzumab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer.
    Dong X; Dai H; Sun A; Yu Z; Du Y
    J Immunol Res; 2022; 2022():9529114. PubMed ID: 35935587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of key genes and pathways involved in trastuzumab-resistant gastric cancer.
    Yu C; Xue P; Zhang L; Pan R; Cai Z; He Z; Sun J; Zheng M
    World J Surg Oncol; 2018 Aug; 16(1):174. PubMed ID: 30134903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioinformatics Analysis of Potential Key Genes in Trastuzumab-Resistant Gastric Cancer.
    Yang G; Jian L; Lin X; Zhu A; Wen G
    Dis Markers; 2019; 2019():1372571. PubMed ID: 31949544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five hub genes contributing to the oncogenesis and trastuzumab-resistance in gastric cancer.
    Chen F; Wang Y; Zhang X; Fang J
    Gene; 2023 Jan; 851():146942. PubMed ID: 36202277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the key pathways and genes involved in HER2-positive breast cancer with brain metastasis.
    Lu X; Gao C; Liu C; Zhuang J; Su P; Li H; Wang X; Sun C
    Pathol Res Pract; 2019 Aug; 215(8):152475. PubMed ID: 31178227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined transcriptome and proteome analysis reveals MSN and ARFIP2 as biomarkers for trastuzumab resistance of breast cancer.
    Shi X; Sheng Y; Fei H; Wei B; Zhang Z; Xia X; Mao C; Si X
    Breast Cancer Res Treat; 2024 Aug; 207(1):187-201. PubMed ID: 38750271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
    Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
    Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in mRNA profiles of trastuzumab‑resistant Her‑2‑positive breast cancer.
    Zhao B; Zhao Y; Sun Y; Niu H; Sheng L; Huang D; Li L
    Mol Med Rep; 2018 Jul; 18(1):139-146. PubMed ID: 29750305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients.
    You JY; Park KH; Lee ES; Kwon Y; Kim KT; Nam S; Kim DH; Bae JW
    Cancer Control; 2023; 30():10732748221141672. PubMed ID: 36814068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 10-Gene Signature for Predicting the Response to Neoadjuvant Trastuzumab Therapy in HER2-Positive Breast Cancer.
    Jia L; Ling Y; Li K; Zhang L; Wang Y; Kang H
    Clin Breast Cancer; 2021 Dec; 21(6):e654-e664. PubMed ID: 34052107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
    Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
    Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in HER2-positive breast cancer.
    Sha R; Dong X; Yan S; Dai H; Sun A; You L; Guo Z
    Sci Rep; 2024 Feb; 14(1):2908. PubMed ID: 38316885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.
    Lee HJ; Seo AN; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
    Br J Cancer; 2015 Jan; 112(1):103-11. PubMed ID: 25349977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
    Takada M; Higuchi T; Tozuka K; Takei H; Haruta M; Watanabe J; Kasai F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Ogawa S; Kaneko Y
    BMC Cancer; 2013 May; 13():241. PubMed ID: 23679233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells.
    Boulbes DR; Chauhan GB; Jin Q; Bartholomeusz C; Esteva FJ
    Breast Cancer Res Treat; 2015 Jun; 151(3):501-13. PubMed ID: 25971596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
    Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance.
    Rezaei Z; Sebzari A; Kordi-Tamandani DM; Dastjerdi K
    DNA Cell Biol; 2019 Feb; 38(2):184-192. PubMed ID: 30702337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
    Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer.
    Seo AN; Lee HJ; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
    Br J Cancer; 2016 May; 114(10):1109-16. PubMed ID: 27115469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.